Despite its controversy, many stem cell research companies have promising technology or methodology with the potential for investors to take a closer look in the area. A recent report by Infiniti Research Limited titled Global Stem Cell Therapy Market 2017-2021, grouped the top growth prospect companies involved in any kind of stem cell therapy-based research.
The International Society for Stem Cell Research defines regenerative medicine as a treatment by administering stem cells, or specific cells that are derived from stem cells in the laboratory; or second, by administering drugs that coax stem cells that are already present in tissues to more efficiently repair the tissue involved.
Regenerative Medicine is defined by the International Society for Stem Cell Research as a treatment that administers stem cells derived from a laboratory or from drugs that coax stem cells already in tissue, to repair organs or tissues that are damaged by disease, aging or trauma.
“Technavio’s analysts forecast the global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021,” read the report.
Here is a look at the top 10 Nasdaq-listed companies included in this report. All figures were provided from Google Finance and current as of June 14 6:30 p.m. EST.
Market cap: $539.54 Million; current share price: $7.50
Originally founded as Sangamo BioSciences, this company seeks to develop new medicines to treat genetic diseases.They have seven products in their pipeline, all involved in different stages of trials and research while collaborating with Shire (NASDAQ:SHPG) and Bioverativ (NASDAQ:BIVV) for another three.
In April the company saw the official retirement of their founder and chairman Edward Lanphier following 21 years working with Sangamo.Recently the company obtained an orphan drug designation from the European Medicines Agency for SB-525, the candidate Sangamo is investigating in collaboration with Pfizer ()
“The therapy is being investigated as a single-treatment strategy intended to provide continuous, therapeutic expression of Factor VIII protein,” indicated the company’s statement.
Market cap: $170.38 Million; current share price: $1.50
Athersys is a biopharmaceutical focused on their MultiStem program, a cell therapy product with off the shelf administration, meaning to need for the patient to submit their own tissue. It is currently under examination for treating inflammatory and immune, neurological, and cardiovascular diseases.
Athersys’ latest financial results highlights that its research and development costs went up to 7.1 million total in the fourth quarter of 2016.
In their latest financial report, the company shared the publication of two articles in peer-reviewed journals, showing results from “how MultiStem cell therapy could provide benefit to patients following ischemic stroke and the second article describing results from Phase 2 trial of MultiStem cell therapy for treating ischemic stroke patients.”
Pluristem Therapeutics (NASDAQ:PSTI)
Market cap: $133.99 million; current share price: $1.36
This clinical-stage biotherapy product develops cell therapy to treat inflammation, ischemia, hematological disorder, or exposure to radiation. Pluristem develops placenta-derived off-the-shelf products.
This company produces their cells in a one of a kind 3D bioreactor that resembles the environment of the human body, which can generate the cells on a mass scale.
During a corporate update based on the financial results for the company on their first quarter of the year, Pluristem President and Co-CEO Yaky Yanay said the company will be able to deliver on the PLX-R18 “product as a medical countermeasure in the treatment of Acute Radiation Syndrome.”
Cellular Biomedicine Group (NASDAQ:CBMG)
Market cap: $103.64 million; current share price: $7.10
This company has its eyes set on China as it hopes to become a leader in the specialty pharmaceutical market for cell therapeutics. Later this year they will open a new facility in Shanghai and expand in Wuxi.
They were recently awarded $2.29 million from the California Institute for Regenerative Medicine for clinical trials of AlloJoin, a stem cell treatment for knee osteoarthritis. As part of their first quarter disclosure, the company stated a net loss for stockholders was for $6.2 million a two million increase from the same period in 2016.
Market cap: $83.67 Million; current share price: $2.65
Vericel bases its treatment in tissue collection from the patient, their two lead products Carticel and Epicel seeking to treat cartilage defects in the knee and patients with burns greater than or equal to 30 percent of total body surface area respectively.
In May the company revealed it had licensed their product portfolio, which includes Carticel, MACI, Ixmyelocel-T, and Epicel, for distribution in China, South Korea, Singapore and more countries in the near region.
For their fourth quarter in 2016, Carticel brought in $12.7 million in revenue while Epicel’s net revenue totaled approximately $3.8 million.
Market cap: $82.54 million; current share price: $4.23
Thanks to their proprietary technology, BrainstormCell converts mesenchymal stem cells into their own NurOwn therapy platform.
The company is training a cell manufacturing team for the production of supplies of NurOwn for an upcoming Phase 3 clinical study for patients with ALS. The company is looking to expand NurOwn into the Canadian market by partnering with the Centre for Commercialization of Regenerative Medicine in Toronto.
Caladrius Biosciences (NASDAQ:CLBS)
Market cap: $41.84 million; current share price: $4.66
Caladrius is investigating its lead product candidate CLBS03 to treat recent-onset type 1 diabetes, currently going through a Phase 2 clinical trial. They plan for this treatment to be autologous.
This cell therapy development company’s total revenue for 2016 totaled $35.3 million, a 57 percent increase from 2015. In their first quarter financials for 2017, the company revealed it had received various funding for its upcoming trials and studies.
Cytori Therapeutics (NASDAQ: CYTX)
Market cap: $32.82 million; current share price: $1.02
Million Recently the company announced the acquisition of assets from Azaya Therapeutics, such as the ATI-0918 drug candidate and announced it plans to develop a nanoparticle-based therapeutics under the name Cytori Nanomedicine in the areas of oncology and regenerative medicine.
Recently the company announced the acquisition of assets from Azaya Therapeutics, such as the ATI-0918 drug candidate and announced it plans to develop a nanoparticle-based therapeutics under the name Cytori Nanomedicine in the areas of oncology and regenerative medicine. They are currently enrolled in a variety of clinical trials for their pipeline of products. They also sell products in Asia Pacific, Europe, and Japan.
They are currently enrolled in a variety of clinical trials for their pipeline of products. They also sell products in Asia Pacific, Europe, and Japan. Recently Cytori introduced their Celution technology, which will see its first product shipments by the third quarter of 2017.
Cesca Therapeutics (NASDAQ:KOOL)
Market cap: $30.30 million; current share price: $3.03
The company recently announced “encouraging” data from a 24 patient study showing the use of autologous platelet-rich plasma to treat chronic non-healing ulcers. Cesca wants their technology to serve the bio-banking and regenerative medicine market.
The company recently announced “encouraging” data from a 24 patient study showing the use of autologous platelet-rich plasma to treat chronic non-healing ulcers. Cesca wants their technology to serve the bio-banking and regenerative medicine market. The company released an update to shareholders following the announcement of their operating results for their fiscal third quarter.
The company released an update to shareholders following the announcement of their operating results for their fiscal third quarter. Dr. Xiaochun “Chris” Xu, chairman and interim chief executive officer said the company established a subsidiary called ThermoGenesis and had obtained the backing and resources from the Boyalife Group.
VistaGen Therapeutics (NASDAQ:VTGN)
Market cap: $30.30 million; current share price: $1.95
This company, which owns subsidiary VistaStem, seeks to develop and commercialize new chemical entities with regenerative potential and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells.
Currently, VisteStem is working on predicting potential heart toxicity of new chemical entities by combining their human pluripotent stem cell technology platform and CardioSafe 3D a human cardiac cell bioassay system.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
This is an updated version of an article first published on the Investing News Network in 2017.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.